This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Champions Oncology To Exhibit And Present 6 Posters At The 2013 AACR Annual Meeting

HACKENSACK, N.J., April 4, 2013 (GLOBE NEWSWIRE) -- Champions Oncology, Inc. (OTC:CSBR) is pleased to announce that it will be presenting six posters on its Champions TumorGraft™ models and Translational Oncology Solutions at the 2013 American Association of Cancer Research (AACR) Annual Meeting being held April 6 - 10 in Washington, DC. Champions will also be exhibiting at the event at Booth #1008.

The posters represent Champions' investment in research and development to expand the value of TumorGraft technology for drug development. The work to be presented will include advancements in targeted TumorGraft model development, characterization of relevant cancer pathways, as well as collaborative work on cancer cachexia models and the utility of next generation DNA sequencing in personalized cancer treatment.

Joel Ackerman, Champions Oncology's CEO, stated, "We are very excited to be presenting several key advancements in our TumorGraft technology platform at the 2013 AACR Annual Meeting. We also look forward to discussing the application of these advancements with the cancer research community during the event."

The posters can be viewed during the following times during the AACR Annual Meeting. For questions, reprints of the posters, or to arrange a meeting with Champions staff during the event, please contact us here.
Poster Title Abstract # Date Time Section # Board #
Integrated next generation sequencing and patient-derived xenografts to personalized cancer treatment 2205 Monday, April 8, 2013 1:00 PM-5:00 PM 42 14
Development of an androgen-dependent prostate Champions TumorGraft™ cancer model 2783 Tuesday, April 9, 2013 8:00 AM - 12:00 PM 19 21
Characterization of spontaneous in vivo cachexia models in Champions TumorGraft™ models 2792 Tuesday, April 9, 2013 8:00 AM - 12:00 PM 19 20
Champions TumorGraft™ models represent oncology clinical trial populations 2779 Tuesday, April 9, 2013 8:00 AM - 12:00 PM 19 26
Champions TumorGraft™ models possess PIK3CA mutations - A great tool to explore the PI3K/AKT pathway 2774 Tuesday, April 9, 2013 8:00 AM - 12:00 PM 19 9
Functional profiling of Champions TumorGraft™ models from metastatic melanoma patients 3498 Tuesday, April 9, 2013 1:00 PM - 5:00 PM 2 16

About Champions Oncology, Inc.

Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company's TumorGraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The Company uses this technology in conjunction with related services to offer solutions for two customer groups: Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through its Personalized Oncology Solutions business.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,776.43 +304.06 1.85%
S&P 500 1,987.05 +35.69 1.83%
NASDAQ 4,781.2640 +73.4890 1.56%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs